Beijing Sun-Novo Pharmaceutical Research Co., Ltd.
SSE:688621.SS
54.23 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 230.84 | 161.793 | 353.202 | 310.32 | 252.264 | 240.116 | 230.957 | 228.613 | 232.434 | 181.366 | 170.932 | 176.349 | 147.96 | 152.549 | 116.983 | 128.344 | 95.771 | 112.826 | 78.829 | 81.932 | 73.769 |
| Cost of Revenue
| 123.338 | 98.674 | 190.926 | 153.18 | 101.968 | 99.938 | 105.246 | 80.712 | 117.875 | 87.757 | 78.369 | 70.799 | 64.223 | 81.317 | 49.26 | 55.832 | 43.557 | 58.5 | 41.283 | 34.929 | 40.312 |
| Gross Profit
| 107.501 | 63.119 | 162.276 | 157.14 | 150.296 | 140.178 | 125.711 | 147.901 | 114.559 | 93.609 | 92.562 | 105.55 | 83.737 | 71.232 | 67.723 | 72.512 | 52.213 | 54.326 | 37.545 | 47.003 | 33.458 |
| Gross Profit Ratio
| 0.466 | 0.39 | 0.459 | 0.506 | 0.596 | 0.584 | 0.544 | 0.647 | 0.493 | 0.516 | 0.542 | 0.599 | 0.566 | 0.467 | 0.579 | 0.565 | 0.545 | 0.482 | 0.476 | 0.574 | 0.454 |
| Reseach & Development Expenses
| 37.729 | 48.136 | 50.412 | 29.23 | 34.967 | 40.558 | 29.763 | 34.028 | 19.335 | 32.987 | 20.571 | 19.335 | 16.793 | 11.9 | 15.901 | 10.119 | 9.656 | 14.257 | 7.195 | 8.759 | 3.981 |
| General & Administrative Expenses
| 24.279 | -55.16 | 62.595 | -14.552 | 24.66 | -56.266 | 61.668 | -13.432 | 26.575 | -49.75 | 57.391 | -12.142 | 20.031 | -29.633 | 36.064 | 3.182 | 1.738 | 2.37 | 2.563 | 3.15 | 1.657 |
| Selling & Marketing Expenses
| 8.175 | -4.783 | -18.916 | 8.934 | 8.514 | 24.39 | 7.563 | 5.25 | 6.589 | 5.896 | 4.495 | 4.619 | 5.263 | 5.546 | 4.591 | 3.415 | 3.479 | 3.726 | 2.44 | 1.424 | 1.121 |
| SG&A
| 32.454 | -59.943 | 44.021 | 44.504 | 33.174 | -31.876 | 69.231 | -8.181 | 33.164 | -43.854 | 61.886 | -7.523 | 25.294 | -24.087 | 40.655 | 6.596 | 5.217 | 6.096 | 5.003 | 4.574 | 2.778 |
| Other Expenses
| 13.876 | 115.039 | 0 | -1.405 | -0.121 | -0.273 | -0.429 | -0.011 | -1.217 | 67.373 | -37.185 | 30.584 | -0.662 | -0.26 | 0 | -0.222 | -0.009 | -0.016 | -0.206 | -0.008 | -0.27 |
| Operating Expenses
| 84.06 | 107.536 | 94.433 | 73.734 | 60.98 | 97.421 | 61.019 | 60.584 | 51.282 | 56.507 | 45.271 | 42.396 | 41.424 | 43.955 | 37.328 | 23.456 | 24.128 | 30.29 | 22.31 | 20.033 | 13.694 |
| Operating Income
| 23.442 | -44.417 | 67.843 | 83.406 | 74.432 | 10.691 | 54.913 | 76.085 | 52.472 | 30.814 | 40.65 | 59.267 | 38.543 | 22.771 | 29.301 | 45.768 | 24.75 | 23.48 | 13.458 | 26.615 | 19.231 |
| Operating Income Ratio
| 0.102 | -0.275 | 0.192 | 0.269 | 0.295 | 0.045 | 0.238 | 0.333 | 0.226 | 0.17 | 0.238 | 0.336 | 0.26 | 0.149 | 0.25 | 0.357 | 0.258 | 0.208 | 0.171 | 0.325 | 0.261 |
| Total Other Income Expenses Net
| -0.17 | -0.124 | -2.133 | -1.405 | -0.121 | -0.273 | -0.429 | -0.011 | -0.051 | 0.043 | -0.181 | -0.129 | 0.131 | -0.26 | 0 | -0.222 | -0.009 | -0.016 | -0.206 | -0.008 | -0.27 |
| Income Before Tax
| 23.272 | -44.541 | 65.71 | 80.508 | 74.311 | 10.418 | 54.484 | 76.074 | 52.421 | 30.857 | 40.469 | 59.138 | 38.674 | 22.512 | 29.301 | 45.546 | 24.742 | 23.464 | 13.252 | 26.606 | 18.961 |
| Income Before Tax Ratio
| 0.101 | -0.275 | 0.186 | 0.259 | 0.295 | 0.043 | 0.236 | 0.333 | 0.226 | 0.17 | 0.237 | 0.335 | 0.261 | 0.148 | 0.25 | 0.355 | 0.258 | 0.208 | 0.168 | 0.325 | 0.257 |
| Income Tax Expense
| -4.08 | -9.754 | 3.258 | 7.902 | 5.568 | 0.172 | 1.144 | 4.663 | 4.522 | 3.174 | -2.832 | 6.92 | 3.835 | 0.669 | 2.663 | 6.51 | 3.466 | 1.187 | 1.534 | 3.001 | 2.399 |
| Net Income
| 29.579 | -30.279 | 59.117 | 75.818 | 72.754 | 13.681 | 53.082 | 70.057 | 47.937 | 27.045 | 41.522 | 53.982 | 33.4 | 20.53 | 26.167 | 38.43 | 20.535 | 21.49 | 10.126 | 23.595 | 17.254 |
| Net Income Ratio
| 0.128 | -0.187 | 0.167 | 0.244 | 0.288 | 0.057 | 0.23 | 0.306 | 0.206 | 0.149 | 0.243 | 0.306 | 0.226 | 0.135 | 0.224 | 0.299 | 0.214 | 0.19 | 0.128 | 0.288 | 0.234 |
| EPS
| 0.27 | -0.27 | 0.53 | 0.68 | 0.65 | 0.12 | 0.47 | 0.63 | 0.43 | 0.24 | 0.52 | 0.68 | 0.42 | 0.36 | 0.43 | 0.64 | 0.24 | 0.36 | 0.17 | 0.4 | 0.21 |
| EPS Diluted
| 0.27 | -0.27 | 0.53 | 0.68 | 0.65 | 0.12 | 0.47 | 0.63 | 0.43 | 0.24 | 0.52 | 0.68 | 0.42 | 0.36 | 0.43 | 0.64 | 0.24 | 0.36 | 0.17 | 0.4 | 0.21 |
| EBITDA
| 26.49 | -40.567 | 69.493 | 101.428 | 78.437 | 30.604 | 73.775 | 94.689 | 70.494 | 47.69 | 57.339 | 74.426 | 52.223 | 34.84 | 40.739 | 51.669 | 25.44 | 26.559 | 16.327 | 29.353 | 21.538 |
| EBITDA Ratio
| 0.115 | -0.251 | 0.197 | 0.327 | 0.311 | 0.127 | 0.319 | 0.414 | 0.303 | 0.263 | 0.335 | 0.422 | 0.353 | 0.228 | 0.348 | 0.403 | 0.266 | 0.235 | 0.207 | 0.358 | 0.292 |